J1627 HCPCS code: Injection, granisetron, extended-release, 0.1 mg
J1627 is the HCPCS Level II code for injection, granisetron, extended-release, 0.1 mg. In 2024 Medicare paid an average of $4.37 per service for J1627 across 1,208,808 services. Its Medicare coverage code is C (Carrier judgment): Coverage is decided by the Medicare contractor (MAC) case by case. The NCCI unit limit is 100 per day on outpatient hospital claims. Medicare volume rose 71% from 2022 to 2024 (706,698 to 1,208,808 services). In 2024, about 259 clinicians billed Medicare for J1627 for 2,680 beneficiaries; Kansas, South Carolina, California accounted for 45% of services.
Code details
| Field | Value |
|---|---|
| Section | J codes — Drugs administered other than oral method |
| Coverage code | C — Carrier judgment |
| Pricing indicator | 51 — Drug or biological (priced per ASP/average sales price rules) |
| BETOS category | O1E — Other drugs |
| Added | 2018-01-01 |
| Last action effective | 2018-01-01 |
Who bills J1627 (2024)
| Measure | Value |
|---|---|
| Clinicians billing (by place of service) | 259 |
| Medicare beneficiaries | 2,680 |
| States with claims | 21 |
| Share of services in top 3 states (Kansas, South Carolina, California) | 45% |
Counts only. Supplier and clinician names, contact lists and state-by-state detail are in Caduvo.
Medicare utilization for J1627, 2022–2024
| Year | Services | Beneficiaries | Avg. allowed | Avg. paid |
|---|---|---|---|---|
| 2022 | 706,698 | 1,863 | $6.25 | $4.99 |
| 2023 | 1,114,432 | 2,570 | $5.88 | $4.68 |
| 2024 | 1,208,808 | 2,680 | $5.48 | $4.37 |
States with the most J1627 services (2024)
| State | Services | Avg. paid |
|---|---|---|
| Kansas | 259,700 | $4.39 |
| South Carolina | 140,600 | $4.33 |
| California | 138,440 | $4.33 |
| Oklahoma | 101,700 | $4.38 |
| Florida | 82,232 | $4.35 |
NCCI unit limits (MUE)
| Claim type | Max units per day | Rationale |
|---|---|---|
| outpatient hospital claims | 100 | Prescribing Information |
| practitioner claims | 100 | Prescribing Information |
What changed for J1627
- 2018-01-01: J1627 added to HCPCS Level II
- Next scheduled CMS quarterly update (HCPCS and DMEPOS fee schedule): 2027-01-01
Frequently asked questions
What is HCPCS code J1627?
J1627 is the HCPCS Level II code for injection, granisetron, extended-release, 0.1 mg. Short descriptor: "Inj, granisetron, xr, 0.1 mg".
How much does Medicare pay for J1627?
In 2024, the average Medicare payment was $4.37 per service (average allowed $5.48).
Does Medicare cover J1627?
Coverage code C — Carrier judgment. Coverage is decided by the Medicare contractor (MAC) case by case.
How many units of J1627 can be billed per day?
100 on outpatient hospital claims; 100 on practitioner claims (NCCI medically unlikely edits).
Related J16 codes
- J1600 — Injection, gold sodium thiomalate, up to 50 mg
- J1602 — Injection, golimumab, 1 mg, for intravenous use
- J1610 — Injection, glucagon hydrochloride, per 1 mg
- J1611 — Injection, glucagon hydrochloride (fresenius kabi), not therapeutically equivalent to j1610, per 1 mg
- J1612 — Injection, glucagon (gvoke), 0.01 mg
- J1620 — Injection, gonadorelin hydrochloride, per 100 mcg
- J1626 — Injection, granisetron hydrochloride, 100 mcg
- J1628 — Injection, guselkumab, 1 mg
- J1630 — Injection, haloperidol, up to 5 mg
- J1631 — Injection, haloperidol decanoate, per 50 mg
- J1632 — Injection, brexanolone, 1 mg
- J1640 — Injection, hemin, 1 mg
Building a device that would bill under a code like this? Caduvo matches a device description to HCPCS/CPT codes, Medicare coverage and payment, and the FDA pathway in one report.
Next steps
- Run a reimbursement report for a device billed under J1627
- Watch J1627 for fee, coverage and descriptor changes
- Build a full Medicare revenue model for J1627
Compiled by Caduvo from public CMS (Medicare) records, HCPCS release October 2026. Fees are Medicare allowables, not commercial rates. Not reviewed or endorsed by CMS. Not billing or legal advice. Report an error. Data and corrections policy.